Johnson & Johnson (JNJ) Non-Current Deferred Tax Liability (2009 - 2026)
Johnson & Johnson recorded quarterly Non-Current Deferred Tax Liability of $7.0 billion in Q1 2026, up 3.24% quarter-over-quarter from $6.8 billion in Q4 2025, and up 188.76% year-over-year from $2.4 billion in Q1 2025.
Johnson & Johnson's Non-Current Deferred Tax Liability history runs 18 years deep, the most recent figure standing at $7.0 billion for Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability rose 188.76% year-over-year to $7.0 billion; the TTM figure through Mar 2026 stood at $7.0 billion (up 188.76% YoY), while the FY2025 annual figure was $6.8 billion, up 177.41% from the prior year.
- Non-Current Deferred Tax Liability came in at $7.0 billion for Q1 2026 at Johnson & Johnson, up from $6.8 billion in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $7.5 billion in Q1 2022 to a low of $2.4 billion in Q1 2025.
- A 5-year average of $4.4 billion and a median of $3.9 billion in 2023 frame the typical range for Non-Current Deferred Tax Liability.
- Across the five-year window, Non-Current Deferred Tax Liability tumbled 46.97% in 2023 and jumped 188.76% in 2026, its largest moves.
- Johnson & Johnson's Non-Current Deferred Tax Liability stood at $4.9 billion in 2022, then plunged by 35.44% to $3.2 billion in 2023, then decreased by 23.33% to $2.4 billion in 2024, then soared by 177.41% to $6.8 billion in 2025, then gained by 3.24% to $7.0 billion in 2026.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $7.0 billion, $6.8 billion, and $6.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 7.01 Bn |
| Mar 29, 2026 | 7.01 Bn |
| Dec 28, 2025 | 6.79 Bn |
| Dec 28, 2025 | 6.79 Bn |
| Sep 28, 2025 | 5.99 Bn |
| Sep 28, 2025 | 5.99 Bn |
| Jun 29, 2025 | 3.80 Bn |
| Jun 29, 2025 | 3.80 Bn |
| Mar 30, 2025 | 2.43 Bn |
| Mar 30, 2025 | 2.43 Bn |
| Dec 29, 2024 | 2.45 Bn |
| Dec 29, 2024 | 2.45 Bn |
| Sep 29, 2024 | 2.95 Bn |
| Sep 29, 2024 | 2.95 Bn |
| Jun 30, 2024 | 2.64 Bn |
| Jun 30, 2024 | 2.64 Bn |
| Mar 31, 2024 | 3.17 Bn |
| Mar 31, 2024 | 3.17 Bn |
| Dec 31, 2023 | 3.19 Bn |
| Dec 31, 2023 | 3.19 Bn |
| Oct 1, 2023 | 2.62 Bn |
| Oct 1, 2023 | 2.62 Bn |
| Jul 2, 2023 | 3.63 Bn |
| Jul 2, 2023 | 3.63 Bn |
| Apr 2, 2023 | 4.42 Bn |
| Apr 2, 2023 | 4.42 Bn |
| Jan 1, 2023 | 3.99 Bn |
| Jan 1, 2023 | 3.99 Bn |
| Oct 2, 2022 | 4.95 Bn |
| Oct 2, 2022 | 4.95 Bn |
| Jul 3, 2022 | 5.02 Bn |
| Jul 3, 2022 | 5.02 Bn |
| Apr 3, 2022 | 6.42 Bn |
| Apr 3, 2022 | 6.42 Bn |
| Jan 2, 2022 | 7.49 Bn |
| Jan 2, 2022 | 7.49 Bn |
| Oct 3, 2021 | 7.15 Bn |
| Oct 3, 2021 | 7.15 Bn |
| Jul 4, 2021 | 9.02 Bn |
| Jul 4, 2021 | 9.02 Bn |
| Apr 4, 2021 | 6.51 Bn |
| Apr 4, 2021 | 6.51 Bn |
| Jan 3, 2021 | 7.21 Bn |
| Jan 3, 2021 | 7.21 Bn |
| Sep 27, 2020 | 5.62 Bn |
| Sep 27, 2020 | 5.62 Bn |
| Jun 28, 2020 | 5.53 Bn |
| Jun 28, 2020 | 5.53 Bn |
| Mar 29, 2020 | 5.77 Bn |
| Mar 29, 2020 | 5.77 Bn |
| Dec 29, 2019 | 5.96 Bn |
| Dec 29, 2019 | 5.96 Bn |
| Sep 29, 2019 | 6.53 Bn |
| Sep 29, 2019 | 6.53 Bn |
| Jun 30, 2019 | 7.73 Bn |
| Jun 30, 2019 | 7.73 Bn |
| Mar 31, 2019 | 7.39 Bn |
| Mar 31, 2019 | 7.39 Bn |
| Dec 30, 2018 | 11.27 Bn |
| Dec 30, 2018 | 11.27 Bn |
| Sep 30, 2018 | 7.71 Bn |
| Sep 30, 2018 | 7.71 Bn |
| Jul 1, 2018 | 7.67 Bn |
| Jul 1, 2018 | 7.67 Bn |
| Apr 1, 2018 | 8.06 Bn |
| Apr 1, 2018 | 8.06 Bn |
| Dec 31, 2017 | 8.37 Bn |
| Dec 31, 2017 | 8.37 Bn |
| Oct 1, 2017 | 4.41 Bn |
| Oct 1, 2017 | 4.41 Bn |
| Jul 2, 2017 | 4.85 Bn |
| Jul 2, 2017 | 4.85 Bn |
| Apr 2, 2017 | 3.31 Bn |
| Apr 2, 2017 | 3.31 Bn |
| Jan 1, 2017 | 2.91 Bn |
| Jan 1, 2017 | 2.91 Bn |
| Oct 2, 2016 | 3.19 Bn |
| Oct 2, 2016 | 3.19 Bn |
| Jul 3, 2016 | 2.85 Bn |
| Jul 3, 2016 | 2.85 Bn |
| Apr 3, 2016 | 2.88 Bn |
| Apr 3, 2016 | 2.88 Bn |
| Jan 3, 2016 | 2.56 Bn |
| Jan 3, 2016 | 2.56 Bn |
| Sep 27, 2015 | 3.56 Bn |
| Sep 27, 2015 | 3.56 Bn |
| Jun 28, 2015 | 3.70 Bn |
| Jun 28, 2015 | 3.70 Bn |
| Mar 29, 2015 | 3.58 Bn |
| Mar 29, 2015 | 3.58 Bn |
| Dec 28, 2014 | 7.54 Bn |
| Dec 28, 2014 | 7.54 Bn |
| Sep 28, 2014 | 4.06 Bn |
| Sep 28, 2014 | 4.06 Bn |
| Jun 29, 2014 | 4.49 Bn |
| Jun 29, 2014 | 4.49 Bn |
| Mar 30, 2014 | 4.59 Bn |
| Mar 30, 2014 | 4.59 Bn |
| Dec 29, 2013 | 7.38 Bn |
| Dec 29, 2013 | 7.38 Bn |
| Sep 29, 2013 | 3.61 Bn |
| Sep 29, 2013 | 3.61 Bn |
| Jun 30, 2013 | 3.69 Bn |
| Jun 30, 2013 | 3.69 Bn |
| Mar 31, 2013 | 3.62 Bn |
| Mar 31, 2013 | 3.62 Bn |
| Dec 30, 2012 | 3.14 Bn |
| Dec 30, 2012 | 3.14 Bn |
| Sep 30, 2012 | 2.72 Bn |
| Sep 30, 2012 | 2.72 Bn |
| Jul 1, 2012 | 2.28 Bn |
| Jul 1, 2012 | 2.28 Bn |
| Apr 1, 2012 | 1.85 Bn |
| Apr 1, 2012 | 1.85 Bn |
| Jan 1, 2012 | 1.80 Bn |
| Jan 1, 2012 | 1.80 Bn |
| Oct 2, 2011 | 1.89 Bn |
| Oct 2, 2011 | 1.89 Bn |
| Jul 3, 2011 | 1.89 Bn |
| Jul 3, 2011 | 1.89 Bn |
| Apr 3, 2011 | 1.90 Bn |
| Apr 3, 2011 | 1.90 Bn |
| Jan 2, 2011 | 1.45 Bn |
| Jan 2, 2011 | 1.45 Bn |
| Oct 3, 2010 | 1.73 Bn |
| Oct 3, 2010 | 1.73 Bn |
| Jul 4, 2010 | 1.67 Bn |
| Jul 4, 2010 | 1.67 Bn |
| Apr 4, 2010 | 1.67 Bn |
| Apr 4, 2010 | 1.67 Bn |
| Jan 3, 2010 | 1.42 Bn |
| Jan 3, 2010 | 1.42 Bn |
| Sep 27, 2009 | 1.51 Bn |
| Sep 27, 2009 | 1.51 Bn |
| Jun 28, 2009 | 1.48 Bn |
| Jun 28, 2009 | 1.48 Bn |